Prospects for the use of fecal microbiota transplantation in obese patients with Type 2 Diabetes Mellitus for weight loss and improvement of insulin sensitivity
https://doi.org/10.14341/DM12716
Abstract
Concerning the uncontrolled growth in the incidence of obesity and Type 2 Diabetes Mellitus (T2DM), numerous research have been carried out to study the pathogenetic mechanisms of progress of these diseases and development of new methods for their prevention and treatment in recent years. T2DM is known to be a multifactorial disease, in the development of which both lifestyle and various environmental factors, and genetic predisposition are involved. At the same time, in recent years, a theory has been discussed that intestinal dysbiosis, which is caused with quantitative and qualitative changes in the gut microbiota (GM) is one of the mechanisms of obesity and T2DM development. At the moment, various methods have been proposed for restoring the normal composition of GM, including the administration of prebiotics and metabiotics that stimulate the growth of gut flora, as well as probiotics, which directly include the necessary beneficial bacteria (mainly Bifidobacterium and Lactobacillus). Fecal microflora transplantation (FMT), which allows transferring an entire microbial community into the recipient's body, rather than individual bacteria is the newest and least studied method of GM normalization. In this connection, this method of GM influencing is of great interest for the prevention and treatment of metabolic diseases.
About the Authors
E. V. Pokrovskaya
Endocrinology Research Centre
Russian Federation
Russian Federation
Elena V. Pokrovskaya, MD, research associate; eLibrary SPIN: 8769-5010
11, Dm. Ulyanova street, 117036 Moscow
I. A. Sklyanik
Endocrinology Research Centre
Russian Federation
Russian Federation
Igor A. Sklyanik, MD, research associate; eLibrary SPIN: 7081-8077
Moscow
E. A. Shestakova
Endocrinology Research Centre
Russian Federation
Russian Federation
Ekaterina A. Shestakova, MD, PhD, leading research associate; eLibrary SPIN: 1124-7600
Moscow
M. V. Shestakova
Endocrinology Research Centre
Russian Federation
Russian Federation
Marina V. Shestakova, MD, PhD, Professor; eLibrary SPIN: 7584-7015
Moscow
References
1. Buse JB, Caprio S, Cefalu WT, et al. How Do We Define Cure of Diabetes? Diabetes Care. 2009;32(11):2133-2135. https://doi.org/10.2337/dc09-9036
2. Di Angelantonio E, Kaptoge S, Wormser D, et al. Association of Cardiometabolic Multimorbidity With Mortality. JAMA. 2015;314(1):52. https://doi.org/10.1001/jama.2015.7008
3. Saeedi P, Petersohn I, Salpea P, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract. 2019;157(1):107843. https://doi.org/10.1016/j.diabres.2019.107843
4. Bellou V, Belbasis L, Tzoulaki I, Evangelou E. Risk factors for type 2 diabetes mellitus: An exposure-wide umbrella review of meta-analyses. PLoS One. 2018;13(3):e0194127. https://doi.org/10.1371/journal.pone.0194127
5. Kahn SE, Cooper ME, Del Prato S. Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. Lancet. 2014;383(9922):1068-1083. https://doi.org/10.1016/S0140-6736(13)62154-6
6. Yu F, Han W, Zhan G, et al. Abnormal gut microbiota composition contributes to the development of type 2 diabetes mellitus in db/db mice. Aging (Albany NY). 2019;11(22):10454-10467. https://doi.org/10.18632/aging.102469
7. Harsch I, Konturek P. The Role of Gut Microbiota in Obesity and Type 2 and Type 1 Diabetes Mellitus: New Insights into “Old” Diseases. Med Sci. 2018;6(2):32. https://doi.org/10.3390/medsci6020032
8. Lazar V, Ditu L-M, Pircalabioru GG, et al. Gut Microbiota, Host Organism, and Diet Trialogue in Diabetes and Obesity. Front Nutr. 2019;6(2):32. https://doi.org/10.3389/fnut.2019.00021
9. Sharma S, Tripathi P. Gut microbiome and type 2 diabetes: where we are and where to go? J Nutr Biochem. 2019;63(2):101-108. https://doi.org/10.1016/j.jnutbio.2018.10.003
10. Kang D-W, Adams JB, Coleman DM, et al. Long-term benefit of Microbiota Transfer Therapy on autism symptoms and gut microbiota. Sci Rep. 2019;9(1):5821. https://doi.org/10.1038/s41598-019-42183-0
11. Fung TC, Olson CA, Hsiao EY. Interactions between the microbiota, immune and nervous systems in health and disease. Nat Neurosci. 2017;20(2):145-155. https://doi.org/10.1038/nn.4476
12. Scott KP, Antoine J-M, Midtvedt T, van Hemert S. Manipulating the gut microbiota to maintain health and treat disease. Microb Ecol Heal Dis. 2015;26(2):145-155. https://doi.org/10.3402/mehd.v26.25877
13. Roberfroid M. Prebiotics: The Concept Revisited. J Nutr. 2007;137(3):830S-837S. https://doi.org/10.1093/jn/137.3.830S
14. Azad MAK, Sarker M, Li T, Yin J. Probiotic Species in the Modulation of Gut Microbiota: An Overview. Biomed Res Int. 2018;2018(3):1-8. https://doi.org/10.1155/2018/9478630
15. Sun J, Buys NJ. Glucose- and glycaemic factor-lowering effects of probiotics on diabetes: a meta-analysis of randomised placebo-controlled trials. Br J Nutr. 2016;115(7):1167-1177. https://doi.org/10.1017/S0007114516000076
16. Żółkiewicz J, Marzec A, Ruszczyński M, Feleszko W. Postbiotics — A Step Beyond Pre- and Probiotics. Nutrients. 2020;12(8):2189. https://doi.org/10.3390/nu12082189
17. Kuznetsova EE, Gorokhova VG, Bogorodskaya SL. The microbiota of intestine. The role in development of various pathologies. Klinicheskaya Laboratornaya Diagnostika. 2016;61(10):723-726. https://doi.org/10.18821/0869-2084-2016-61-10-723-726
18. Karpukhin OY, Khasanov ER, Bikbov BSh. Transplantation of fecal microbiota in modern clinical practice. Prakticheskaya meditsina. 2017;(6):7-12. (In Russ.).
19. Aron-Wisnewsky J, Clément K, Nieuwdorp M. Fecal Microbiota Transplantation: a Future Therapeutic Option for Obesity/Diabetes? Curr Diab Rep. 2019;19(8):51. https://doi.org/10.1007/s11892-019-1180-z
20. Wang J-W, Kuo C-H, Kuo F-C, et al. Fecal microbiota transplantation: Review and update. J Formos Med Assoc. 2019;118(8):S23-S31. https://doi.org/10.1016/j.jfma.2018.08.011
21. de Groot PF, Frissen MN, de Clercq NC, Nieuwdorp M. Fecal microbiota transplantation in metabolic syndrome: History, present and future. Gut Microbes. 2017;8(3):253-267. https://doi.org/10.1080/19490976.2017.1293224
22. Hasan N, Yang H. Factors affecting the composition of the gut microbiota, and its modulation. Peer J. 2019;7(3):e7502. https://doi.org/10.7717/peerj.7502
23. Wilson BC, Vatanen T, Cutfield WS, O’Sullivan JM. The Super-Donor Phenomenon in Fecal Microbiota Transplantation. Front Cell Infect Microbiol. 2019;9(3):e7502. https://doi.org/10.3389/fcimb.2019.00002
24. Backhed F, Ding H, Wang T, et al. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci. 2004;101(44):15718-15723. https://doi.org/10.1073/pnas.0407076101
25. Turnbaugh PJ, Ley RE, Mahowald MA, et al. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature. 2006;444(7122):1027-1031. https://doi.org/10.1038/nature05414
26. Ridaura VK, Faith JJ, Rey FE, et al. Gut Microbiota from Twins Discordant for Obesity Modulate Metabolism in Mice. Science (80-). 2013;341(6150):1241214. https://doi.org/10.1126/science.1241214
27. Zhang P, Li L, Han X, et al. Fecal microbiota transplantation improves metabolism and gut microbiome composition in db/db mice. Acta Pharmacol Sin. 2020;41(5):678-685. https://doi.org/10.1038/s41401-019-0330-9
28. Wang H, Lu Y, Yan Y, et al. Promising Treatment for Type 2 Diabetes: Fecal Microbiota Transplantation Reverses Insulin Resistance and Impaired Islets. Front Cell Infect Microbiol. 2020;9(5):678-685. https://doi.org/10.3389/fcimb.2019.00455
29. Vrieze A, Van Nood E, Holleman F, et al. Transfer of Intestinal Microbiota From Lean Donors Increases Insulin Sensitivity in Individuals With Metabolic Syndrome. Gastroenterology. 2012;143(4):913-916.e7. https://doi.org/10.1053/j.gastro.2012.06.031
30. Kootte RS, Levin E, Salojärvi J, et al. Improvement of Insulin Sensitivity after Lean Donor Feces in Metabolic Syndrome Is Driven by Baseline Intestinal Microbiota Composition. Cell Metab. 2017;26(4):611-619.e6. https://doi.org/10.1016/j.cmet.2017.09.008
31. Yu EW, Gao L, Stastka P, et al. Fecal microbiota transplantation for the improvement of metabolism in obesity: The FMT-TRIM double-blind placebo-controlled pilot trial. PLOS Med. 2020;17(3):e1003051. https://doi.org/10.1371/journal.pmed.1003051
32. Wilson BC, Vatanen T, Cutfield WS, O’Sullivan JM. The Super-Donor Phenomenon in Fecal Microbiota Transplantation. Front Cell Infect Microbiol. 2019;9(3):e1003051. https://doi.org/10.3389/fcimb.2019.00002
33. Sunkara T, Rawla P, Ofosu A, Gaduputi V. Fecal microbiota transplant – a new frontier in inflammatory bowel disease. J Inflamm Res. 2018;Volume 11(3):321-328. https://doi.org/10.2147/JIR.S176190
34. Zhang F, Cui B, He X, et al. Microbiota transplantation: concept, methodology and strategy for its modernization. Protein Cell. 2018;9(5):462-473. https://doi.org/10.1007/s13238-018-0541-8
35. Kelly CR, Kahn S, Kashyap P, et al. Update on Fecal Microbiota Transplantation 2015: Indications, Methodologies, Mechanisms, and Outlook. Gastroenterology. 2015;149(1):223-237. https://doi.org/10.1053/j.gastro.2015.05.008
36. Gupta A, Saha S, Khanna S. Therapies to modulate gut microbiota: Past, present and future. World J Gastroenterol. 2020;26(8):777-788. https://doi.org/10.3748/wjg.v26.i8.777
37. Wang S, Xu M, Wang W, et al. Systematic Review: Adverse Events of Fecal Microbiota Transplantation. PLoS One. 2016;11(8):e0161174. https://doi.org/10.1371/journal.pone.0161174
Supplementary files
Review
For citations:
Pokrovskaya E.V., Sklyanik I.A., Shestakova E.A., Shestakova M.V. Prospects for the use of fecal microbiota transplantation in obese patients with Type 2 Diabetes Mellitus for weight loss and improvement of insulin sensitivity. Diabetes mellitus. 2020;23(6):541-547. (In Russ.) https://doi.org/10.14341/DM12716
Views:
1070
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
